Cannara Biotech (TSE:LOVE) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Cannara Biotech Inc. has reported record-breaking sales growth and operating cash flow for fiscal 2024, achieving a 43% increase in annual revenue and a 3.2% national market share. The company’s strong financial performance, marked by a 14th consecutive quarter of positive Adjusted EBITDA and significant improvements in free cash flow, underscores its robust position in Canada’s cannabis market. Looking ahead, Cannara plans to expand its production capacity with new grow zones in 2025, aiming to further strengthen its market standing.
For further insights into TSE:LOVE stock, check out TipRanks’ Stock Analysis page.